An abstract is a record that contains information about each patient from the time of diagnosis and continuing throughout his or her life. The abstract includes patient data about demographics, diagnostic studies, cancer staging, treatment, and follow-up. When they create and update abstracts, cancer registrars must follow abstracting rules set by their individual state central registries. Hospitals that are accredited through the American College of Surgeons Commission on Cancer (ACoS/CoC) also follow ACoS/CoC abstracting rules and standards. Cancer registries transmit abstract data to their state’s cancer registry and, if the facility is ACoS/CoC-accredited, to the National Cancer Data Base (NCDB).
Views: 2864 NCRA News
Speaker: PD Dr. med. Jens Hasskarl, Hematologist, Oncologist, Global Clinical Leader CTL019 Novartis Pharma AG, Basel (CH) "Pushing the Limits in Novel Medicine ‐ Gene Transfer, Cells, Targeting, Materials" Chair Dr. med. h.c. Beat Löffler, MA, European Foundation for Clinical Nanomedicine, Basel (CH) and Prof. Dr. Lajos P. Balogh, Editor‐in‐Chief, Nanomedicine, Nanotechnology, Biology and Medicine, Elsevier and Member of the Executive Board, American Society for Nanomedicine, Boston (USA)) Day 2 Hall Montreal CLINAM 2015 The European Summit for Clinical Nanomedicine and Targeted Medicine – The Translation to Knowledge Based Medicine Eighth Conference and Exhibition, June 30 2015
Views: 374 TAUVOD
There are about 60 well-established workplace carcinogens, and still more to-be-identified occupational carcinogens. Yet Canada still lacks a rapid, systematic means to assess increased cancer risk associated with occupational exposures. Although Canada collects timely and high quality information on every new cancer that is diagnosed through provincial and national registries, occupational cancer surveillance data has been limited by the lack of information on industry and occupation. In a pilot study, a research team linked Workplace Insurance and Safety Board (WSIB) lost-time claims data with the Ontario Cancer Registry (OCR). In this plenary, Dr. Paul Demers, director of the Occupational Cancer Research Centre, discusses the results of the pilot study, focusing on the feasibility of this new approach to assessing and monitoring workplace risk factors for cancer.
Views: 141 IWH Research
The risk factors for cancer are many and varied, and inherited genetic mutations play a major role in 5 to 10% of all cancers. When these mutations are identified early, patients are able to work with their healthcare providers to take crucial steps toward care and treatment. Comments on this video are allowed in accordance with our comment policy: http://www.cdc.gov/SocialMedia/Tools/CommentPolicy.html This video can also be viewed at https://www.cdc.gov/video/phgr/2016/GR_04-19-2016-lo-res.mp4
Views: 1625 Centers for Disease Control and Prevention (CDC)
The mission of the UNC Cancer Care Brain Metastases Specialty Clinic is to improve outcomes, enhance quality of life, and offer new therapeutic strategies for patients with brain metastases arising from breast cancer and other solid tumors.
Views: 358 UNC Lineberger
The Lancet Oncology Commission: Future Cancer Research Priorities in the USA — Part 2 Top scientists discuss how they recommend expanding and implementing the Blue Ribbon Panel’s road map for cancer research. They’ll discuss a report that will be published by the journal The Lancet Oncology and is co-edited by Elizabeth Jaffee, M.D., deputy director of the Johns Hopkins Kimmel Cancer Center, and Chi Van Dang, M.D., Ph.D., scientific director at Ludwig Cancer Research and professor at The Wistar Institute. Visit Johns Hopkins inHealth at: https://www.hopkinsmedicine.org/inhealth
Views: 117 Johns Hopkins Medicine
https://www.advisory.com/Research/Oncology-Roundtable/Multimedia/Video/2015/Why-your-prostate-cancer-volumes-are-declining Prostate cancer volumes are experiencing a steep decline: according to the Florida Cancer Data System, the number of new cases fell by nearly half between 2011 and 2013. What's powering this dramatic shift, and what trends can cancer programs expect in the future? In our video, we break down data available in The Journal of the American Medical Association and explain what factors are behind the drop in prostate cancer diagnoses, from new screening guidelines to the use of active surveillance. We also talk about how these numbers will change going forward.
Views: 157 Advisory Board
Speaker: Dave Viskochil, MD, PhD, University of Utah This is an original presentation from the 2018 NF Forum that took place in Atlanta, Georgia in May of 2018. The NF Forum allows those living with NF, and their families, to connect, support, and learn from each other while attending seminars on relevant topics pertaining to neurofibromatosis. To enable closed captioning, click the CC button. To learn more about the NF Forum, go to: http://ctf.org/nfforum
Views: 39 childrenstumor
As a family practice physician, medical epidemiologist, researcher and administrator, Anne Lanier has worked to improve health among Alaska’s Native people since 1967. Starting as a physician at the Alaska Native Medical Center, she saw too many young Alaska Native people dying of cancer. She asked why and, finding no answers, she determined to seek them. In 1974 Lanier created the Alaska Native Tumor Registry, one of 18 National Cancer Institute’s Surveillance Epidemiology and End Results registries, to determine cancer rates and patterns throughout the U.S. Her data-driven research has led to dramatic declines in incidence and mortality rates in pediatric liver and cervical cancer among Alaska’s Native people. She always published her data so others could review her conclusions. Lanier was the first female director of the Centers for Disease Control and Prevention’s Arctic Investigations Program. She initiated the Alaska Native Epidemiology Center and later created the Alaska Native Health Consortium’s Office of Alaska Native Health Research. Lanier currently is a consultant for the Alaska Native Tribal Health Consortium in Anchorage. In 1982 Lanier became a Fellow of the American Board of Preventative Medicine. In 2011 she received the inaugural Carol Frieden Award for Extraordinary Leadership in Comprehensive Cancer Control from the Centers for Disease Control and Prevention. After graduating from Lawrence University in Appleton, Wis., in 1962, Lanier earned her M.D. degree from Washington University School of Medicine in 1966 and completed a Masters of Public Health degree at the University of Minnesota School of Public Health in 1975. She did an internship at Presbyterian Hospital in Denver, Colo., before taking her first job in Alaska. Lanier has three children and five grandchildren. She is a reader, skier, kayaker, and traveler. She has mentored several generations of health researchers and personally funds a scholarship at the University of Alaska Anchorage for those pursuing master’s degrees in public health.
Views: 4 Alaska Women's Hall of Fame
While we know about the rise in this disease in those under 50, recent studies put an alarming fact into hard focus: you're never too young for colon cancer. Hematology-oncology specialist Dr. Jason Zell discusses this trend, as well as new research showing that the science behind this disease is changing. #TheAntiCancer | http://www.anti-cancer.com Get patient stories, wellness tips, health care news and more on our Live Well blog: http://www.ucirvinehealth.org/blog UC Irvine Health | http://www.ucirvinehealth.org
Views: 171 UCI Health
Three NCI researchers and grantees discuss how minority participation in clinical research can benefit ethnic and underserved populations. African American, Asian American, and Hispanic populations are featured.
Views: 455 National Cancer Institute
While there isn't a cure to diagnosed primary brain tumors, 35,000 individuals are diagnosed each year. A diagnosis like this raises questions for patients and their loved ones about what the future holds -- from available treatment options to appropriate care. This panel touches upon the different stages of treatment, the various operational procedures available and the practices of post-surgery rehabilitation. Guests include: Joseph C. Landolfi, DO, Medical Director, JFK Brain Tumor Center; Allison Hoffman, Patient of Dr. Landolf; Ilana Unger, MS, OTR/L, Senior Occupational Therapist, Kessler Institute for Rehabilitation; Stan Shrodo, Support Group Leader, The Central New Jersey Brain Tumor Support Group & Resource Center 12/29/12 #2420
Views: 960 Steve Adubato
Presentation given by Allen Dearry, Program Director, NIH, on the National Cancer Institute (NCI) Cancer Research Data Commons, at Big Data IWG meeting on 06/28/2018. Presentation outline: "National Cancer Data Ecosystem; NCI Cancer Research Data Commons; Data Linkages: Cancer Data Aggregator, Encrypted Unique Patient Identifier; Collaboration/coordination: Partnerships, Office of Data Sharing."
Views: 49 NITRD Program
VOICE OF DOCTOR MAURICEHILLEMAN Bill Gates And The SV40 Cancer-Causing Virus By David Jenkins 6-22-11 Read at: http://rense.com/general94/bill.htm The new (GMO-DNA) vaccines contain SV40. Wikipedia, in an article on DNA vaccination includes this reference to SV40: "The SV40 promoter was conventionally used until research showed that vectors driven by the Rous Sarcoma Virus (RSV) promoter had much higher expression rates. ... An example of DNA vaccine plasmid is pVAC, it uses SV40 promoter. The SV40 Cancer Foundation, however, goes into more detail. "SV40 was the 40th virus found in rhesus monkey kidney cells when these cells were used to make the polio vaccine. This virus contaminated both the Inactivated Polio Vaccine (IPV) created by Dr. Jonas Salk and the Oral or "Live" Polio Vaccine (OPV) created by Dr. Albert Sabin. "In 1961, SV40 was discovered by Dr. Bernice Eddy of the National Institute of Health, Division of Biologics when she took the material used to grow polio vaccines and injected it into hamsters. Tumors grew in the hamsters. Her discovery was subsequently validated by Drs. Maurice Hilliman and Benjamin Sweet of Merck. Children being fed sugar cubes with the oral polio vaccine. Circa 1961. "Upon the discovery that SV40 was an animal carcinogen that had found its way into the polio vaccines, a new federal law was passed in 1961 that required that no vaccines contain this virus. However, this law did not require that SV40 contaminated vaccines be thrown away or that the contaminated seed material (used to make all polio vaccines for the next four decades) be discarded. As a result, known SV40 contaminated vaccines were injected into children up until 1963. In addition, it has been alleged that there have been SV40-contaminated batches of oral polio vaccine administered to some children until the end of the 1990's. Dr. Robert Bell, once Vice President International Society for Cancer Research at the British Cancer Hospital said: "The chief, if not the sole, cause of the monstrous increase in cancer has been vaccination." Hillerman, chief of vaccines at Merck not only validated Bernice Eddy's discovery but he admitted that all Merck's vaccines contain cancer viruses and other viruses and that their Hepatitis vaccine caused the AIDS epidemic in the US. Dr. Larry Palevsky, a NY board certified pediatrician, agrees as well that vaccines contain viruses and says that most of the viruses in vaccines can not be removed. The new vaccines are GMO-DNA vaccines. The material that they wish to inject has been genetically engineered (thus GMO) using parts of viruses, cancers, animal poxes, and combined, and are then shot or inhaled or injected into the body, to be "taken up by the DNA" (thus DNA) . This material is meant to affect the body in the most fundamental way possible, by affecting the very coding of the body (the DNA) which controls functions for the existence of the person. And doesn't SV40's potential uptake by the child or adult's DNA present a much graver danger than previously? Could this cancer virus now become part of the body's coding itself? SV40 was removed by federal law. So, is against federal law to introduce it into vaccines again? And is it not an extreme threat to anyone taking the new vaccines, to have it taken up by their DNA? Bill Gates wants every newborn on earth registered for vaccination, with cell phones to alert parents as well as locate people. The Redmond, Wash.-based company's cofounder and chairman envisioned collecting biometric information on babies via handsets and transmitting the data to a central health registry, which could be used to remind parents about vaccinations. GPS data from the phone could also help guide medical personnel to remote locations to administer vaccines. Continue reading at: http://rense.com/general94/bill.htm Other: SV40 CANCER FOUNDATION http://www.sv40foundation.org/CPV-link.html Transcript of audio interview with Dr. Maurice Hilleman http://www.naturalnews.com/033584_Dr_Maurice_Hilleman_SV40.html
Views: 36 TEXAS LIBERTY ADVOCATE NETWORK ACTION
The American Board of Clinical Neuropsychology (ABCN; member board of the American Board of Professional Psychology [ABPP]), in collaboration with the American Academy of Clinical Neuropsychology’s (AACN) Relevance 2050 Student Pipeline Subcommittee, is proud to announce a webinar aimed at increasing early education on board certification via ABPP/ABCN for graduate students, interns, postdoctoral fellows, and early-career psychologists. Dr. Linas Bieliauskas will talk about the process of becoming board-certified, its importance and advantages. Drs. Pamela Dean and Jason Soble will share their experiences going through the process as well as resources and recommendations for current and future applicants. Attendees will be able to submit questions to be addressed by the speakers during the Q&A. We look forward to having you join us!
Views: 1408 AACN Relevance 2050 Student Pipeline Subcommitee
Part of a monthly NCI webinar series, Research to Reality, on various topics related to cancer control and prevention, this webinar explores how state/local health departments, cancer registries, academic institutions, and community organizations are collaborating to implement public health genomics programs. Presenters share experiences and offer lessons learned for others to implement similar cancer control genomics programs in their own communities.
Views: 131 National Cancer Institute
On September 25, 2010 the Caring for Carcinoid Foundation held its first Neuroendocrine Tumor Patient Education Conference at Stanford University's Alumni Center in Palo Alto California, USA. This day-long event was attended by over 100 patients and caregivers and featured neuroendocrine tumor experts from Stanford University and UCSF Medical Center. An important feature of this event was launch of Stanford Cancer Center's participation in the CFCF Neuroendocrine Tumor Bioconsortium. This Bioconsortium links the tissue biobanks at five centers which specialize in neuroendocrine tumor research and patient care. The project is a multi-institutional research program funded by Caring for Carcinoid Foundation and described in this presentation by Dr. Pamela Kunz. There was also a fundraising walk and run held the evening before the conference, which raised over $10,000 for the Bioconsortium project. To learn more, please visit www.caringforcarcinoid.org
Views: 390 Caring4Carcinoid
September 6, 2017 Lecture Title: Bringing Genomics to the Pediatric Oncology Clinic: Diagnosis, Treatment Selection and Rational Clinical Trial Design More: https://www.genome.gov/27568937
Views: 280 National Human Genome Research Institute
"We Were There" lecture series' latest lecture video titled "How a Rare Cancer Changed the Workplace and Environment - PVC and Angiosarcoma" Comments on this video are allowed in accordance with our comment policy: http://www.cdc.gov/SocialMedia/Tools/CommentPolicy.html This video can also be viewed at http://www.cdc.gov/video/WWT_PVC/WWT-Rare_Cancer_04-24-2018_LowRes.mp4
Join Kyle Brown of Invitae, as he discusses the importance of creating an online patient profile. By registering on lungcancerregistry.org, lung cancer patients can contribute to a growing collection of data that drives important decisions in the medical arena.
Views: 48 Addario Lung Cancer Foundation
April 4, 2014 - The 2014-2015 Genomics in Medicine Lecture Series More: http://www.genome.gov/27556434
Views: 2620 National Human Genome Research Institute
Amyotrophic lateral sclerosis (ALS), sometimes called Lou Gehrig’s disease, is a rapidly progressive, fatal neurological disease caused by degeneration of motor neurons in the brain and spinal cord. Researchers don’t know what causes ALS and there is no cure. Approximately 80 percent of persons with ALS die within 2-5 years of diagnosis. Comments on this video are allowed in accordance with our comment policy: http://www.cdc.gov/SocialMedia/Tools/CommentPolicy.html This video can also be viewed at https://www.cdc.gov/video/phgr/2017/GR_04-18-2017.mp4
This is one of fifteen videos recorded by the Fibrous Dysplasia Foundation at the 2014 Patient and Family Conference. It was held at the NYU Langone Medical Center, New York, NY on October 25-26, 2014. Fibrous Dysplasia Foundation website: http://www.fibrousdysplasia.org Speaker Information: Charles W. Harles Charlie Harles was a founder and is now president of the Fibrous Dysplasia Foundation, established to provide information, advocacy, support, and research on FD, Mc-Cune Albright Syndrome and cherubism. Charlie was first diagnosed at age seven or eight and did not meet another person with FD/MAS until he was over 50 years old. Charlie has been participating in several studies and advocating for persons with FD and MAS at NIH. Though Charlie has had to use crutches or a wheelchair since childhood and has had many fractures and surgeries, he pursued a legal career (JD from University of North Carolina) focused on providing job training and employment for persons with disabilities. Dr. Michael Collins Dr. Collins is the Chief of the Skeletal Clinical Studies Unit at National Institutes of Health in Bethesda, Maryland. His research is focused on the study of bone biology and mineral metabolism. One of his primary foci of research is fibrous dysplasia of bone and McCune-Albright syndrome. Dr. Collins is the author of many scholarly articles on FD/MAS and has cared for more than 200 patients with FD/MAS over the last 15 years at the NIH. He has dedicated a large part of his career to advancing the understanding of FD/MAS, improving the quality of life of patients with FD/MAS through better treatments. He has been involved with the FD Foundation since its inception and serves on the Board of Medical Advisors to the Foundation.
Views: 1179 FD Foundation Inc
Stephen Chanock M.D. from the National Cancer Institute presents Genome-wide association studies in Cancer: A Step in the Right Direction
Views: 1145 NCIwebinars
Medical Radiation and cancer risk: assessing the price of progress Air date: Friday, January 11, 2013, 12:00:00 PM Category: NIH Director's Seminars Runtime: 01:02:02 Description: NIH Director's Seminar Radiation exposure to the US population from diagnostic imaging has increased 6-fold in the last three decades, primarily due to the rapid increase in CT scans from 1 to 80 million per year. Despite the great medical benefits there are concerns about the potential future cancer risks from CT and other higher dose imaging tests such as nuclear medicine cardiac stress tests. Dr. Berrington's Radiation Epidemiology Branch conducted the first study to directly assess the cancer risks after CT scans in a historical cohort study of 200,000 children in the UK. Dr. Berrington will discuss the first results from this study and also present risk projections for the number of future cancers in the US that may be related to diagnostic imaging in children and adults if use continues at current levels. Recently a number of new screening tests such as lung CT and CT colonography have been proposed for use in the general population, and newer radiotherapy techniques like proton therapy have become more widespread. Dr. Berrington will also describe work that she has conducted that assesses the balance of the potential benefits against the radiation-related cancer risks for these emerging technologies. Permanent link: https://videocast.nih.gov/launch.asp?17744
Views: 439 nihvcast
In this myth shattering, information packed documentary, learn from physicians and leading researchers about medicinal cannabis and its demonstrated effects on human health. This game-changing movie presents the most comprehensive synopsis to date of the real science surrounding the world's most controversial plant. Topics include: * What the consensus is from over 1500 scientific and medical trials * What conditions have been proven to benefit from medical marijuana * Its historical use as medicine dating back over 5300 years * Methods of delivery and their different advantages * Government sponsored studies intended to show Marijuana having negative effects that yielded the exact opposite results * Common myths about negative effects of Marijuana and what the research really says about these topics Doctors: Dr. David Bearman Expert Witness Former Director of Haight Ashbury Drug Treatment Program Founder of Isla Vista Medical Clinic Member of Governor Reagan's Inter-Agency Task Force on Drug Abuse Dr. Donald TashkinDr. Donald Tashkin Emeritus Professor of Medicine UCLA Medical Director of UCLA Pulmonary Function Laboratory Dr. Donald AbramsDr. Donald Abrams Director, Integrative Oncology Research Program Integrative Medicine Physician. Professor of Clinical Medicine at UCSF and Chief of Hematology/Oncology at San Francisco General Hospital Dr. Robert SternerDr. Robert Sterner UCSD General Surgeon Graduate of Harvard & UCLA Certified in Oriental and Traditional Chinese Medicine Credits: * James Schmachtenberger (Executive Producer) * Lindsey Ward (Director/Producer) * Troy Brajkovich (Director of Photography) Visit: http://www.MarijuanaMovie.Org Directors YT: MindzEyeFilm Download Link: http://v20.lschache4.c.youtube.com/Medical%20Cannabis%20and%20Its%20Impact%20on%20Human%20Health%20a%20Cannabis%20Documentary.mp4 (you might need to right click and "save as") Captions text link: http://textuploader.com/?p=6&id=BDe7j
Views: 440447 HolisticPlantHealth .channel
Measles outbreaks linked to unvaccinated children on the mainland have many in Hawaii questioning whether our vaccination requirements are strong enough to prevent an outbreak here. Although several vaccinations are required to attend public schools, parents who believe the shots are dangerous or unnecessary can seek exemptions for religious and medical reasons. But now that the nearly eradicated measles virus has returned, should exemptions for healthy children still be allowed? Malia Mattoch moderates this discussion.
Views: 6731 PBSHawaiiorg
Sheila K. Riggs Radiation Oncology Center The Radiation Oncology Center provides advanced radiation therapy to cancer patients. GBMC offers 3D conformal radiation therapy, intensity modulated radiation therapy (IMRT), imaged- guided radiation therapy (IGRT), transperineal prostate implants, a wide array of brachytherapy treatments, stereotactic radiosurgery, and radioimmunotherapy. Through participation in national clinical trials, the department helps identify and bring the most promising therapies and new cancer treatments to our patients as soon as possible. For example, GBMC was the first community hospital in the area and one of few institutions nationwide to offer the sophisticated Intensity Modulated Radiation Therapy (IMRT) to oncology patients. The Radiation Oncology Center is a statewide model of excellence. Patient care is paramount. All patients are provided with the highest quality of radiotherapeutic care. Board-certified radiation oncologists and a board-certified medical physicist are on staff. Patient satisfaction survey results show that 97% of the patients participating in the survey have had a good to excellent experience. A recent special medical report issue of Baltimore Magazine named each of the radiation oncologists as "Top Doctors". The Top Doctor recognition is a peer-review honor, where fellow physicians name doctors who they would recommend to loved ones. Radiation therapy is multidisciplinary. It requires teamwork from a variety of professionals to provide quality care to cancer patients. Our radiation oncology team consists of radiation oncologists, radiation oncology nurses, radiation therapists, medical dosimetrists, medical physicists, medical assistant, secretaries, receptionists, and volunteers. The radiation oncologist is the patient's physician in the department. He or she is board certified with the American Board of Radiology to treat cancer with radiation. The radiation oncologist prescribes the dose of radiation and manages the patient's treatment and/or side of effects. In addition, the radiation oncologist follows the patient's post treatment. Radiation oncology nurses work closely with the radiation oncologist to manage side effects. This includes educating the patient about side effects and the necessary steps to minimize side effects. The nurses also make recommendations about diet and skin care. Radiation therapists are health care professionals certified in radiation therapy by the American Registry of Radiologic Technology. Radiation therapists deliver the radiation treatment by operating the linear accelerator. Radiation therapists also participate in the simulation process and aid in the education of patients. Medical dosimetrists are responsible for providing treatment plans that meet and adhere to the radiation oncologist prescription. Medical physicists are responsible for providing clinical physics service and quality assurance. Medical assistants work in all aspects of department work, such as clerical, nursing, and radiation therapist duties. Secretaries are responsible for the radiation oncologists' schedules and making sure that the physicians have all necessary records for consultations. The receptionists greet patients daily and schedule follow up appointments.
Views: 1165 Greater Baltimore Medical Center
Join us on July 24-26th to learn about the latest Google Cloud innovations and get an insider's view of Next 18. Featuring: Keynotes, Spotlight Sessions, Showcase demos, keynote recaps, interviews with industry experts, inspirational cloud stories and more. 8.30AM-9.00AM- Keynote Pre-show 9.00AM-10.30AM: Keynote: Building a Cloud for Everyone 10.30AM-11.00AM: Interviews with experts, product demos, and the latest news 11.00AM-11.50AM: Application Migration and Hybrid Deployments in a Multi-Cloud World 11.50AM-12.35PM: Interviews with experts, product demos, and the latest news 12.35PM-1.35PM: Healthcare and Life Sciences in the Cloud | AI in Healthcare and Biomedical Research 1.35PM-2.30PM: Interviews with experts, product demos, and the latest news. 2.30PM-3.30PM: Customer Keynote: Google Cloud Customer Innovation Series-Tuesday 4.00PM-4.50PM: Recording: Serverless on Google Cloud 4.50PM-5.00PM: Interviews with experts, product demos, and the latest news. Learn more and view the event schedule → http://g.co/next18 Subscribe to the Google Cloud channel → http://bit.ly/NextSub
Views: 58100 Google Cloud
What is reproductive surgery? Learn more at http://obgyn.ucla.edu
Views: 302 UCLA Health
Hear from a panel of experts in the field of lung cancer diagnosis, treatment and future advancements. Learn the importance and benefits of individualized or “precision medicine” when being treated for lung cancer. Filmed on March 23, 2017 in Sacramento, CA. Moderator: Dr. Costanzo DiPerna, MD -Dignity Health- Thoracic Surgeon Panel: Dr. Megan Daly, MD- UC Davis- Radiation Oncology Dr. Deepti Behl, MD-Sutter-Medical Oncology Dr. Peter Murphy, MD- Dignity Health- Pulmonology Rachel McConachie-Dignity Health-Nurse Navigator
Views: 250 Addario Lung Cancer Foundation
In May 2014, NCI’s Division of Cancer Epidemiology and Genetics (DCEG) hosted “Cancer Epidemiology: From Pedigrees to Populations,” a scientific symposium honoring 50 years of visionary leadership by Dr. Joseph F. Fraumeni, Jr., the founding Director of DCEG. In this video, Dr. Stephen Chanock of NCI provides opening remarks. Dr. David Schottenfeld of the University of Michigan moderates a session on the search for cancer susceptibility genes. Dr. Louise Strong of University of Texas MD Anderson Cancer Center speaks about the discovery and future challenges of Li-Fraumeni syndrome research. For more information on this symposium, visit http://dceg.cancer.gov/news-events/Fraumeni-symposium-speakers
Views: 616 National Cancer Institute
Lynch syndrome (LS) is an inherited disorder that raises a person’s risk of developing colorectal, endometrial (uterine), ovarian, stomach, and other forms of cancer. Expanded screening for Lynch syndrome has been widely recommended due to the potential benefits to both patients and their family members, but has not yet been fully implemented throughout the United States. Join us for the March 21, 2017 Research to Reality cyber-seminar to learn more about Lynch syndrome, universal tumor screening, and some reflections from a National Cancer Institute hosted workshop focused on LS. David Chambers, MSc, DPhil, will give a brief overview of the webinar and provide some key takeaways from the NCI hosted workshop, ‘Approaches to Blue Ribbon Panel Recommendations: The Case of Lynch Syndrome’, convening on February 23 and 24, 2017. Heather Hampel, MS, LGC, will provide an overview of Lynch syndrome, current screening practices, and the benefits of universal tumor screening for LS. Greg Feero, MD, PhD, will discuss some of the issues that must be addressed to improve the identification and management of individuals at risk for hereditary cancer syndromes in primary care settings, and how his pilot project is approaching this issue. Debra Duquette, MS, CGC, will share ways in which the Michigan Department of Health and Human Services Cancer Genomics Program promotes awareness of and best practices surrounding Lynch syndrome. She will also describe the Lynch Syndrome Screening Network, a resource for health systems interested in implementing routine LS screening. The presenters will share their experiences working with the Lynch Syndrome Screening Network and reflect on their experiences at the NCI-hosted workshop. The final part of the webinar will offer an opportunity for participants to engage with the presenters. We encourage you to share your own experiences and thoughts! An archive of the cyber-seminar may be accessed at: https://researchtoreality.cancer.gov/cyber-seminars/expanding-lynch-syndrome-screening-research-reality
Views: 105 NCIwebinars
Brainlab has been a key player in the field of precision radiotherapy and radiosurgery for over two decades. Over those twenty years, radiosurgery has moved from being a very special procedure that only a handful of institutions provided to a mainstream treatment. Patient access has improved with the large number of institutions that have adopted Linac radiosurgery. Today, 750 of the top 1000 cancer centers around the globe use Brainlab software. What is the future role of Brainlab in radiosurgery? We spent lots of time and resources on going back to the drawing board and taking a deeper look at the fundamental challenges in precision radiotherapy. How can we leverage our technology to improve the lives of patients with cancer? Watch the video to find out more or visit our radiosurgery page at http://brai.nl/B59I3073JTX
Views: 8221 Brainlab
Cancer has emerged as the leading cause of death in low- and middle-income countries. Many countries, especially in sub-Saharan Africa are ill prepared to handle this evolving crisis in medical care. Building on the successful collaborative partnership centered on HIV-AIDS is the AMPATH-Oncology program (the Academic Model for Providing Access to Healthcare), which is focused on enhancing the research, educational and clinical care infrastructure for western Kenya. This presentation will provide the background and current status of this ongoing experiment in health care delivery. View the other videos in this series www.cancer.gov/globalhealth/events/seminarseries
Views: 457 NCIwebinars
The Translational Cancer Research Network (TCRN) is a Translational Cancer Research Centre based at UNSW and funded by the Cancer Institute NSW. Founded in 2011, the TCRN brings together researchers and clinicians from across its member groups including UNSW Sydney, hospitals within the South East Sydney Local Health District, University Technology Sydney, Border Medical Oncology and the Australian Institute of Health Innovation. The Cancer Institute identified translational research as an area to focus research support to supplement the usual research funding models that focus upon preclinical scientific discovery or clinical trials. The focus of such research is intended to be on mainstream application of novel approaches to care emerging from preclinical or preliminary clinical research or clinical observation leading to novel directions for preclinical research. The goals of the TCRN are to foster a sustainable culture of translational research and develop a sustainable cancer focussed workforce. Examples of the TCRN work in biobanking and bioinformatics and hereditary cancer will be used as examples of potential system change, identification of potential metrics to assess impact in partnership with the AIHI, and our planned future program will be outlined. Professor Goldstein is a conjoint clinical professor at the UNSW Prince of Wales Clinical school. He is the director of the UNSW Cancer Institute NSW Translational Cancer Research Centre – the Translational Cancer Research Network [TCRN] of which the AIHI is a key member. The TCRN belongs to a network of centres established to aggregate translational cancer research in NSW. He has been involved in a variety of clinical research projects ranging from laboratory basic science to novel therapeutics trials to psychosocial aspects of Cancer care. He has been PI of a number of NHMRC and Cancer Australia funded therapeutic trials including both investigator initiated and as Australian PI for multinational studies. He has also been involved with psychosocial and cross cultural/CALD research for many years. His clinical interests are treatment of GI malignancies including pancreas cancer, colorectal cancer, anal carcinoma, hepatobiliary and upper GI malignancy and renal cell carcinoma and lymphoma. He is the adult program leader of the newly formed UNSW Cancer Survivors Centre and is involved with a research program associated with survivorship issues. As part of this activity, he is the Chief Investigator of a Cancer Institute NSW translational program grant of $3,100,000 to study the impact of chemotherapy induced peripheral neuropathy. He also actively participates in three laboratory research programs dealing with stromal biology, pancreas drug resistance and modelling optimal targeted therapies in sarcoma. Professor Goldstein has over 250 co-authored peer reviewed publications and has presented at numerous national and international meetings: USA – ASCO, Japan - Japan Pancreas Society, Gastro week and medical oncology group, New Zealand, S. Korea, Singapore, COSA ASM. Professor Goldstein is a past president of the Clinical Oncology Society of Australia and was a long serving board member of the Australasian Gastrointestinal Trials Group over 11 years and was treasurer for most of that time. He is currently the project leader for the ASCO/HVO cancer program in Hue Vietnam, as well as being a member of the supervisory committee of all HVO cancer projects.
Views: 170 The Macquarie University Community
https://www.instagram.com/prometei.tech/ reassured screamed liter favoring traction wondered reconsider realizing plow nap brain's ebb manifests CVD HDL minutiae ducks They've sufficed proponents waged salvo yearlong Tulane coverage unanimously sarcasm Pundits predictors coffin headlines representative enrolled Asians demographic diehards implausible slashing upped group's balloons publicized uptick bioelectrical impedance predictor LDL carbers pedestrian cuttingsome glean takeaways echoed study's Lydia Bazzano compel directing dogmatic almighty Jake fascinating devoting installment I’ve mmols Wingates foggy acuity tissue's oxidize Phinney synonymous Mistaking intriguing teamed Auburn Wolfe's CPT impede trash Someone's calorically reintroduction reintroduce blunts Paoli transitioned lasted Ketostix conservatively reversals lackluster telltale stroll tantamount deluge chockfull edibles aisle Who's les courgettes serrated peeler spiralizer wonderfully hash browns mandolin dubbed cauliflower's spuds pulverize Brassica wallop Chard sauté cremini shiitake fungi umami portobello stealthily praised dearth smear firepower backlash au naturale pint shrivelled rosy orbs lycopene Nature's lengthwise microwavable parchment scrape benevolent gourd Radish Bok choy Watercress famously sang stoned sweetness tinged tipoff nondigestible plush stellar sniffles pucker Fillets mercury unseasoned marinades ante beloved deli spared lunchmeats Dijon collard fests fattened Cornish hen Gruyere mundane decoupled riff blending pinches mop cultured surging critters tangy horns cow's Brie Ricotta kefir carnivores soaks brilliantly marinate Tempeh earthy mushroomy crumbling casseroles sauerkraut Pinto boast Pepitas o castoffs Sargento stringy bathed humming lofty healthyomega shops supermarkets Pepperettes Hazelnuts Bob's fare Shirataki translucent gelatinous konjac bowlful nondescript rinse blanch Preliminary prediabetes viscous Hazelnut brewed quencher moo cartons sidestep Imbibing infuses exhaustive flapjacks marys ye sipped seltzer contradictory farther swilling interchangeably insulinogenic spur counterintuitive accessing tougher adjusts Mozzarella cucumbers kcals reservoir thriving ongoing chow insisted French's Trimmed Uncured Portabella condensed tamari aminos steamer bubbly Ruthie ours marshmallows dye pumpkins fl Truvia Nutmeg Cloves towels masher lumpy quartered ½ generously pierced family's else's cleanup cooks Kosher slits slit PDF unwrap tossed bowl's ooohs aaaahs mouthwatering Coarse wilt bakes Sprouted crumb crumbs crumble byproducts apiece appreciable granite unconditioned stepmill app Centopani eater groundbreaking world's Evan's insists com's it'd befriending fluke flounder rutabaga turnips distributing rigors regimented hamburgers Animal's flagship Pak negotiable fundamentally depleting plows wishful oversimplified depletes Karbolyn Labrada's shuttling muscles replenished proponent dragging microtraumas pounder resynthesis disposal polymer shuttle Elasti RTD MRP EFA Charge Krill MPS rapamycin hesitate Centopani's diner steakhouse wheelbarrow Overseas border nearest awful refrigeration Stak Iconic XL Beanie Rotisserie precooked breaded standby powered brothers McGrath Antoine Vaillant baggie brainer Nothing's comforting goulash Slurp swole requested dad's bursting rotini parsnips I’ll paprika Worcestershire Caraway saucepot batch Printable Frosting silicone brethren Vincenzo Masone Fritz approached days steal sanitary basa jumbo gallbladder crowns handfuls plums nectarines underconsumed drilled skulls lid poking USDA thickest translates clump cruciferous broil cardamom thankfully occasions roasting dicing drizzling facet pectin midworkout plump insides glorious skimp Tahini Cumin pretzels sing Ramen entrée zing sharpest leftover pinapple Endive chilies clove crumbles vinaigrette Kalamata pitted Oregano Bragg's tonight's Mendelsohn frothy stove fortunate micromanaging achievements NASCAR skimping mussels rabbit seitan grapefruits limes Melons honeydew apricots… chestnuts overanalyzing fistful plateauing stricter fistfuls arrangement honing afforded it'll Fiber's Satiate Yep compiled SOUTHWEST potlucks bevy ROMA SEEDED uncovered BALSAMIC yummy clocks heats PARSNIP resealable rimmed Discard FE COB THINLY spinner BURRITO RINSED GARNISHES STROGANOFF CAMPBELL'S SHERRY dente garnished Dorian coveted GROUNDED hesitation filets tenderloins scours tags grabs fattier semblance beefing thrifty exchanges D's rodeo beeline Quaker swayed canister opts canisters measly sizzling sitcom Kris EZ sec Bathe proverbial anticipate Radar Benchmarks Robergs R Pearson Costill Fink J Pascoe Benedict Zachweija intensities Calder Yaqoob Bowtell Gelly Simeoni Rennie Wang uncompromising Welsh Kage meditative yin coincides iconoclast's sellers efficaciously replicate brand's Vitargo disguise bitterness reluctantly Offerings Hydra underperforming refilming raced biked deadlifted Ironman Matt Pritchard Ironmans swears triathletes Trainee Hey faceless
Views: 47361 ПРОКАЧКА
The National Institute of Nursing Research (NINR) Big Data in Symptoms Research Boot Camp, part of the NINR Symptom Research Methodologies Series, is a one-week intensive research training course at the National Institutes of Health (NIH) in Bethesda, Maryland. NINR's 2015 Boot Camp provided a foundation in data science focusing on methodologies and strategies for incorporating novel methods into research proposals. Since there was a high demand for the course, the first day of the Big Data Boot Camp was videocast live and is now available in segments on the NINR YouTube channel. To learn more visit www.ninr.nih.gov/bootcamp. Part 3 features Dr. Bonnie Westra of the University of Minnesota discussing Big Data Analytics for Healthcare.
Views: 876 NINRnews
Children's Tumor Foundation Webinar Transforming NF Research: Children's Tumor Foundation as a Bridge Between Researchers, Clinicians, and Biotech Panelists: John Risner, President, Children's Tumor Foundation Annette Bakker, Chief Scientific Officer, Children's Tumor Foundation Moderator: Simon Vukelj, Director of Communications, Children's Tumor Foundation *** Please note the captioned text was provided in a rough‑draft format by Communication Access Realtime Translation (CART), which is provided in order to facilitate communication accessibility and may not be a totally verbatim record of the proceedings.
Views: 664 childrenstumor
September 14, 2017 - The Consumer Product Safety Commission hears from interested persons on the petition requesting that the Commission initiate rule making under the Federal Hazardous Substances Act (FHSA).
Views: 263 U.S. Consumer Product Safety Commission
Dr. Paul Turek, an international thought leader on men's health issues, will present an overview of sexual health for men at any age. This talk will address the concepts and cures for common sexual issues such as low sex drive, infertility, hormonal disturbances and other conditions that affect reproduction.
Views: 22762 Talks at Google
Please visit: www.openpediatrics.org OPENPediatrics™ is an interactive digital learning platform for healthcare clinicians sponsored by Boston Children's Hospital and in collaboration with the World Federation of Pediatric Intensive and Critical Care Societies. It is designed to promote the exchange of knowledge between healthcare providers around the world caring for critically ill children in all resource settings. The content includes internationally recognized experts teaching the full range of topics on the care of critically ill children. All content is peer-reviewed and open access-and thus at no expense to the user. For further information on how to enroll, please email: email@example.com Please note: OPENPediatrics does not support nor control any related videos in the sidebar, these are placed by Youtube. We apologize for any inconvenience this may cause.
Views: 5233 OPENPediatrics
The Role of Telehealth in an Evolving Health Care Environment Workshop TOPIC #4: Current Evidence Base Panel moderator: Kamal Jethwani, Partners Healthcare Center for Connected Health; Harvard Medical School Current Research Base Elizabeth Krupinski, University of Arizona Using data to change policies or standards of care (tele-Stroke) Lee Schwamm, Massachusetts General Hospital; Harvard Medical School Q&A with Audience
Views: 8656 NASEM Health and Medicine Division
A first for Canada, the Tripartite First Nations Health Plan calls on BC, Canada, and BC First Nations to work together to close the health gap. Drawing on the wisdom of our indigenous neighbours -This chapter outlines a vision for increased First Nations control over the design and delivery of health services.
Views: 3424 fnhealthcouncil